Clinical trial · Interventional
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer
NCT00534807CI-TRIAL-00018997withdrawnPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test how vinflunine interacts with rifampin in the human body
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rifampin | Drug | — | UNRESOLVED |
| Vinflunine | Drug | Vinflunine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The Primary Outcome Measure of the effect of rifampin on the pharmacokinetics (PK) of intravenous (IV) vinflunine will be determined from the PK measurements
- timeFrame
- taken during Cycle 2 of study treatment, at approximately 4 weeks after the start of study treatment
Secondary outcomes (1)
- measure
- The Secondary Outcome Measures of the safety and tolerability of vinflunine when administered alone and with rifampin
- timeFrame
- determined after 2 complete 21-day Cycles of study treatment, at approximately 6 weeks after the start of study treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer unresponsive to previous treatment * Consent for genetic samples Exclusion Criteria: * Cancer of the blood * Spread of cancer to the brain * Moderate or severe nerve damage * Low white blood cell counts and platelet counts * Inadequate liver or kidney function * Prior treatment with vinflunine * Use of certain medications that might interfere with the metabolism of vinflunine
References
Publications (0)
Data not yet available
No reference posted for this study.